Translating Clinical Trial Expertise from Dermatology to Gastrointestinal Disorders
March 6, 2026
As immune-mediated inflammatory diseases converge across specialties, the connection between dermatology and gastrointestinal research has never been more apparent—and more important. This article explores how shared cytokine pathways, biologic therapies, and operational strategies allow dermatology expertise to translate seamlessly into GI trials. Read it now to discover how Symbio bridges therapeutics to accelerate timelines and strengthen data quality in inflammatory studies.
Enhance Your Dermatology Clinical Trials With Symbio
Specialization and Partnership for Richer Insights and Seamless Execution
February 2, 2026
Dermatology and aesthetic clinical trials are uniquely challenging: Many endpoints are subjective, timelines are short, and competition for patients and sites is intense. Partner with Symbio for specialized expertise, global reach, and exceptional service that reduce variability, streamline operations, and remove uncertainty at every step.
TRANSLATING CLINICAL TRIAL EXPERTISE
Dermatology to Gastrointestinal Disorders
September 2, 2025
The need for therapeutic innovation across specialties is made evident by the increasing prevalence of immune-mediated inflammatory diseases (IMIDs). Through common immunopathology, primarily the dysregulation of cytokines, dermatology and gastroenterology are closely related.
CLINICAL TRIAL SPOTLIGHT
Trends in Atopic Dermatitis: Treatments and Trial Design
October 10, 2024
The last two years have seen a surge in proposed and initiated clinical trials for atopic dermatitis (AD), or eczema.
REGULATORY SPOTLIGHT
Insights into Annex XVI – Article 3 of 3: “Prerequisites for a Clinical Investigation of Medical Devices without a Medical Purpose”
July 24, 2024
Are you planning a clinical investigation in the complex landscape of medical device regulations, particularly concerning products without a medical purpose (Annex XVI, REGULATION (EU) 2017/745 (MDR)?
REGULATORY SPOTLIGHT
Insights into Annex XVI – Article 2 of 3: “Clinical Investigations of Medical Devices without a Medical Purpose”
June 21, 2024
Are you navigating the complex landscape of Medical Device Regulations (MDR) concerning products without a medical purpose (Annex XVI, MDR)? Symbio can help!
REGULATORY SPOTLIGHT
Insights into Annex XVI – Article 1 of 3: “Designing the Investigator’s Brochure”
June 5, 2024
This article highlights the “guidance on content of the Investigator's Brochure for clinical investigations of medical devices - MDCG 2024-5,” recently published by the Medical Device Coordination Group (MDCG). The guideline is helpful in creating the Investigator's Brochure, a key document in the submission package to NCAs, and helps avoid queries in the submission process.
This guideline is also applicable for products listed in Annex XVI of REGULATION (EU) 2017/745-Medical Device Regulation (MDR). Annex XVI lists products without an intended medical purpose which are nevertheless covered by MDR.